Tariffs on imported pharma could go up to 250%, U.S. President Trump says

/2 min read

ADVERTISEMENT

The impact of tariffs could erode profits of Indian pharmaceutical firms and also slam the brakes on R&D. India is also under Trump’s scanner, who has warned that reciprocal tariffs will be raised substantially.
Tariffs on imported pharma could go up to 250%, U.S. President Trump says
U.S. President Donald Trump Credits: Getty Images

U.S. President Donald Trump said that tariffs on imported pharmaceuticals can be as much as 250 percent after initially levying a “small tariff” and then spiking it to 150 percent to give a fillip to domestic production of pharmaceuticals.

Trump, who was speaking to CNBC in an interview, did not specify what the initial tariffs on pharmaceuticals would be. The U.S. has been undertaking a national security review of the pharmaceutical sector. It is not known when the results of the review will be announced, but the industry has been taking contingency measures, preempting sector-specific tariffs. More recently, AstraZeneca said that it has earmarked an investment of $50 billion to expand manufacturing and research facilities in the U.S. by 2030.

According to data compiled by Nomura, pharmaceuticals make up about 37% of India’s sectoral exports, with 12% of the exports going to the U.S. While pharmaceuticals and electronics are exempted from reciprocal tariffs under the U.S. Section 232 trade investigations, any sectoral tariffs levied on pharmaceuticals will be passed on to end-consumers, which, in turn, would affect the export volumes.

Fortune India Latest Edition is Out Now!
40u40: India's Brightest Young Business Minds

July 2025

In the world’s youngest nation—where over 65% of the population is under 35—India’s future is already being shaped by those bold enough to lead it. From boardrooms to breakout ideas, a new generation of business leaders is rewriting the rules. This year's Fortune India’s 40 Under 40 celebrates these changemakers—icons in the making like Akash Ambani, Kaviya Kalanithi Maran, Shashwat Goenka, Parth Jindal, Aman Mehta, and Devansh Jain—who are not just carrying forward legacies but boldly reimagining them for a new era. Alongside them are first-generation disruptors like Sagar Daryani, scaling Wow! Momo with a vision to take ₹100 momos to 5,000 cities, and Palak Shah, turning the Banarasi weave into a global fashion story with Ekaya Banaras. These are the entrepreneurs turning ambition into scale. And even beyond traditional industry, the entrepreneurial wave is pulling in creative forces—Ranveer Singh, for instance, is shaking up wellness and nutrition with Bold Care and SuperYou, proving that passion, backed by purpose, is the new blueprint for building brands.

Read Now

Sanjaya Mariwala, the executive chairman and managing director of OmniActive Health Technologies, said that pharmaceuticals and electronics would take the biggest hit with the imposition of tariffs and a fine for importing oil from Russia.

Beyond the monetary implications, the tariffs would interrupt smooth trade flow, inflate U.S. drug costs, stall treatments, and could even put greater pressure on American healthcare budgets. “Back home, the profits for Indian pharmaceutical companies may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances,” he said.

Trump also told CNBC that it will impose substantially higher tariffs on India in the next 24 hours, a day after he launched a fresh salvo at India over the import of oil from Russia. His comments came close on the heels of the Indian government issuing a strong rejoinder against Trump’s threats, repudiating that the U.S. is unfairly targeting India when imports by the U.S. and the EU were much higher than India’s.

Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.

Related Tags